ZGNX Zogenix Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 17 December 2019 The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome

   FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Zogenix,

2. 05 December 2019 Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

   EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its

3. 02 December 2019 JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

   Addition of FINTEPLA to stiripentol-inclusive regimens provided a 54% greater reduction in study patients' mean monthly convulsive seizure frequency compared to placeboA significantly greater proportion of study patients

4. 02 December 2019 Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting

   EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its

5. 27 November 2019 Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

   EMERYVILLE, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a

6. 25 November 2019 Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome

   EMERYVILLE, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has

7. 12 November 2019 Zogenix to Present at Two Investor Conferences in November

   EMERYVILLE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and

8. 07 November 2019 Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results

   Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndromeEnrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020Acquired Modis Therapeutics, Inc.;

9. 31 October 2019 Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7

   EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the

10. 25 October 2019 Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome

    Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction in high-risk

11. 07 October 2019 Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

    Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion

12. 26 September 2019 Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application

13. 09 September 2019 Zogenix Completes Acquisition of Modis Therapeutics, Inc.

    EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition

14. 03 September 2019 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

15. 29 August 2019 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

16. 26 August 2019 Zogenix Announces Acquisition of Modis Therapeutics, Inc.

    Advances Zogenix's strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2